These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

15 related articles for article (PubMed ID: 8901025)

  • 1. Cloning, characterization, and functional studies of a human 40-kDa catecholamine-regulated protein: implications in central nervous system disorders.
    Gabriele J; Pontoriero GF; Thomas N; Thomson CA; Skoblenick K; Pristupa ZB; Mishra RK
    Cell Stress Chaperones; 2009 Nov; 14(6):555-67. PubMed ID: 19280369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent affinity labeling of brain catecholamine-absorbing proteins using a high-specific-activity substituted tetrahydronaphthalene.
    Ross GM; McCarry BE; Mishra RK
    J Neurochem; 1995 Dec; 65(6):2783-9. PubMed ID: 7595578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cocaine treatment increases expression of a 40 kDa catecholamine-regulated protein in discrete brain regions.
    Sharan N; Chong VZ; Nair VD; Mishra RK; Hayes RJ; Gardner EL
    Synapse; 2003 Jan; 47(1):33-44. PubMed ID: 12422371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Halothane enhances dopamine metabolism at presynaptic sites in a calcium-independent manner in rat striatum.
    Adachi YU; Satomoto M; Higuchi H; Watanabe K; Yamada S; Kazama T
    Br J Anaesth; 2005 Oct; 95(4):485-94. PubMed ID: 16113039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of brain catecholamine absorbing proteins by dopaminergic agents.
    Modi PI; Kashyap A; Nair VD; Ross GM; Fu M; Savelli JE; Marcotte ER; Barlas C; Mishra RK
    Eur J Pharmacol; 1996 Mar; 299(1-3):213-20. PubMed ID: 8901025
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.